# Diversity Supplement: Targeting chemoresistant prostate cancer with novel EED inhibitors

> **NIH NIH R01** · CLARK ATLANTA UNIVERSITY · 2023 · $59,167

## Abstract

This Diversity Supplement will train Ms. Skylar Grayson, a highly qualified African American researcher, in
cancer research and prepare her for a doctoral program in biological sciences, clinical pharmacology, or
toxicology. Ms. Grayson will participate in the Specific Aims 2 and 3 as outlined in the parent grant, specifically,
evaluating the in vitro and in vivo activities of new EED inhibitors against chemoresistant PCa in preclinical
models and determining the drug-like properties and toxicology of lead compounds. We will provide a
candidate-specific training environment to maximize Ms. Grayson’s potential as a graduate student in
pharmacology or toxicology.

## Key facts

- **NIH application ID:** 10747516
- **Project number:** 3R01CA256058-02S1
- **Recipient organization:** CLARK ATLANTA UNIVERSITY
- **Principal Investigator:** DAQING WU
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $59,167
- **Award type:** 3
- **Project period:** 2022-04-01 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10747516

## Citation

> US National Institutes of Health, RePORTER application 10747516, Diversity Supplement: Targeting chemoresistant prostate cancer with novel EED inhibitors (3R01CA256058-02S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10747516. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*